AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

AFT PHARMACEUTICALS LIMITED Share Issue/Capital Change 2021

Jun 20, 2021

64327_rns_2021-06-20_08e2a070-00b8-4d57-9ef6-e02035abd532.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

==> picture [159 x 86] intentionally omitted <==

Capital Change Notice

21 June 2021

Issue of ordinary shares

This notice is given under NZX Listing Rule 3.13.1 and relates to the issue of ordinary shares in AFT Pharmaceuticals Limited under the AFT Pharmaceuticals Limited Long Term Incentive Plan.

Section 1: Issuer information

Name of issuer	AFT Pharmaceuticals Limited
NZX ticker code	AFT
Class of financial product	Ordinary shares
ISIN (If unknown, check on NZX website)	NZAFTE0001S4
Currency	NZD
Section 2: Capital change details
Number issued	10,000
Nominal value (if any)	Not applicable
Issue price per security	$2.80
Nature of the payment	Not applicable
Amount paid up (if not in full)	In full
Percentage of total class of Financial Products issued(calculated on the number of Financial Products of the	0.01%
Class, excluding any Treasury Stock, in existence)
For an issue of Convertible Financial Products or	Not applicable
Options, the principal terms of Conversion
Reason for issue and specific authority for issue	10,000 shares were issued to an
	employee exercising options under the
	AFT Pharmaceuticals Limited Long
	Term Incentive Plan
Total number of Financial Products of the Class after	104,663,875
the issue (excluding Treasury Stock) and the total
number of Financial Products of the Class held as
Treasury Stock after the issue.
Specific authority for the issue, including a reference	Directors’ resolution, Listing Rule 4.6
to the rule pursuant to which the issue is made
Terms or details of the issue (for example: restrictions,	The ordinary shares issued rank pari
escrow arrangements)	passu with the existing ordinary shares
Date of issue	18 June 2021

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 [email protected]

Section 3: Authority for this announcement and contact person	Section 3: Authority for this announcement and contact person
Name of person authorised to make thisannouncement	Malcolm Tubby
Contact person for this announcement	Malcolm Tubby
Contact phone number	+64 9 488 0232
Contact email address	[email protected]
Date of release through MAP	21 June 2021